Clinical Trials Logo

Clinical Trial Summary

This study will assess possible drug-drug interactions with specific isoenzymes over a total study duration of 6-8 weeks. Blood samples collected pre and post-dose, and urine samples collected post dose will be analyzed.


Clinical Trial Description

This is an open-label, multiple-dose, non-randomized study to assess the drug-drug interactions of Proellex® with cytochrome P450 isoenzymes in healthy female subjects. On Day 1, following an overnight fast and morning void of the bladder, subjects will be administered CYP probe drugs orally. Serial blood samples will be collected at pre-dose and post-dose. Subjects will be administered two Proellex® 25 mg capsules (50 mg total dose) at approximately 0800 hours on Day 2 and 0700 hours on Days 3 through 8. One hour after administration of Proellex® on Day 8, the five CYP probe drugs will be administered and blood and urine samples collected as on Day 1. Blood samples for the determination of plasma concentrations of CDB-4124 and its metabolite CDB-4453 will be collected at pre-dose (trough) on Days 6, 7, and 8 to determine if steady-state conditions have been achieved. Samples will also be collected on Day 8 at 1, 2, 8 and 24 hour after administration of Proellex® to determine the plasma concentrations of CDB-4124 and CDB-4453. ;


Study Design

Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00741468
Study type Interventional
Source Repros Therapeutics Inc.
Contact
Status Completed
Phase Phase 1
Start date July 2008
Completion date October 2008

See also
  Status Clinical Trial Phase
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT01925638 - Effect of Ketoconazole on the Pharmacokinetics of Refametinib Phase 1
Completed NCT00621699 - Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects Phase 1
Completed NCT00442585 - S(+)-Ibuprofen Effects on Asprin Treated Volunteers Phase 1
Completed NCT00200759 - Drug Interactions and Bioavailability of Cranberry Phase 1
Active, not recruiting NCT06401863 - Shared Decision for Drug Interactions in Oral Anticoagulation N/A
Completed NCT00915746 - A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers Phase 1
Completed NCT03748745 - A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects Phase 1
Completed NCT03324685 - A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen Phase 1
Completed NCT05433896 - Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions Phase 1
Recruiting NCT03307863 - Effect of Anti-epileptic Drugs on Etonogestrel-releasing Implant Pharmacokinetics in Women With Epilepsy Phase 4
Completed NCT02706535 - A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential Phase 1
Completed NCT02147808 - A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects Phase 1
Completed NCT02097953 - Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin Phase 0
Completed NCT01364987 - Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers Phase 1
Completed NCT00709982 - A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM) /Ethinyl Estradiol (EE) in Healthy Women. Phase 1
Completed NCT00810303 - Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2 Phase 1
Completed NCT04252300 - Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants Phase 1
Completed NCT02576366 - Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus Phase 4
Completed NCT02159326 - Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women Phase 1